Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

Patients with hidradenitis suppurativa experience knowledge gaps on effective treatments and addressing these gaps could help ...

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Coherus Biosciences (CHRS – Research Report). The associated price ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...

EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...